Nicotinamide adenine dinucleotide (NAD + ) synthetase catalyzes the last step in NAD + biosynthesis. Depletion of NAD + is bactericidal for both active and dormant Mycobacterium tuberculosis (Mtb). By inhibiting NAD + synthetase (NadE) from Mtb, we expect to eliminate NAD + production which will result in cell death in both growing and nonreplicating Mtb. NadE inhibitors have been investigated against various pathogens, but few have been tested against Mtb. Here, we report on the expansion of a series of urea-sulfonamides, previously reported by Brouillette et al. Guided by docking studies, substituents on a terminal phenyl ring were varied to understand the structure-activity-relationships of substituents on this position. Compounds were tested as inhibitors of both recombinant Mtb NadE and Mtb whole cells. While the parent compound displayed very weak inhibition against Mtb NadE (IC 50 = 1000 μM), we observed up to a 10-fold enhancement in potency after optimization. Replacement of the 3,4-dichloro group on the phenyl ring of the parent compound with 4-nitro yielded 4f, the most potent compound of the series with an IC 50 value of 90 μM against Mtb NadE. Our modeling results show that these ureasulfonamides potentially bind to the intramolecular ammonia tunnel, which transports ammonia from the glutaminase domain to the active site of the enzyme. This hypothesis is supported by data showing that, even when treated with potent inhibitors, NadE catalysis is restored when treated with exogenous ammonia. Most of these compounds also inhibited Mtb cell growth with MIC values of 19-100 μg/mL. These results improve our understanding of the SAR of the ureasulfonamides, their mechanism of binding to the enzyme, and of Mtb NadE as a potential antitubercular drug target.
NAD + production which will result in cell death in both growing and nonreplicating Mtb. NadE inhibitors have been investigated against various pathogens, but few have been tested against Mtb. Here, we report on the expansion of a series of urea-sulfonamides, previously reported by Brouillette et al. Guided by docking studies, substituents on a terminal phenyl ring were varied to understand the structure-activity-relationships of substituents on this position. Compounds were tested as inhibitors of both recombinant Mtb NadE and Mtb whole cells. While the parent compound displayed very weak inhibition against Mtb NadE (IC 50 = 1000 μM), we observed up to a 10-fold enhancement in potency after optimization. Replacement of the 3,4-dichloro group on the phenyl ring of the parent compound with 4-nitro yielded 4f, the most potent compound of the series with an IC 50 value of 90 μM against Mtb NadE. Our modeling results show that these ureasulfonamides potentially bind to the intramolecular ammonia tunnel, which transports ammonia from the glutaminase domain to the active site of the enzyme. This hypothesis is supported by data showing that, even when treated with potent inhibitors, NadE catalysis is restored when treated with exogenous ammonia. Most of these compounds also inhibited Mtb cell growth with MIC values of 19-100 μg/mL. These results improve our understanding of the SAR of the ureasulfonamides, their mechanism of binding to the enzyme, and of Mtb NadE as a potential antitubercular drug target.
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Mycobacterium tuberculosis; NadE; antibiotic; antitubercular Tuberculosis (TB), caused by the bacillus Mycobacterium tuberculosis (Mtb), remains one of the world's deadliest infectious diseases. [1] [2] [3] According to the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS), 10.4 million people fell ill and 1.8 million died from TB in 2015, which is 0.7 million more than those who died from HIV-related illnesses. 1, 2 Besides the high prevalence of TB, the large number of new cases of multi-drug resistant (MDR) and extensively-drug resistant (XDR) TB has made the disease a more serious public health concern. 2 Two of the most important first-line TB drugs (isoniazid, rifampicin) are both ineffective against MDR-TB and XDR-TB, rendering the treatment options very limited. 4, 5 Thus, there remains a pressing need for novel drugs that shorten TB treatment and are effective against all pathogenic strains.
Nicotinamide adenine dinucleotide (NAD + ) is a ubiquitous enzyme cofactor, indispensable for reduction-oxidation reactions as well as essential nonredox functions in the cell such as cell longevity, telomere maintenance, Ca 2+ signaling, DNA repair, and immune response. 6, 7 NAD + synthetase (NadE) is an essential enzyme that catalyzes the last step in many NAD + de novo biosynthesis and NAD + recycling pathways. 8, 9 In Mtb, NadE transforms nicotinic acid adenine dinucleotide (NaAD + ) into NAD + via a two-step process with the assistance of ATP and ammonia ( Figure 1 ). [8] [9] [10] [11] [12] [13] Ammonia is obtained from glutamine hydrolysis in the glutaminase domain of the enzyme. [8] [9] [10] [11] [12] [13] Inhibition of NadE blocks NAD + biosynthesis and leads to cell death in both growing and nonreplicating Mtb. [14] [15] [16] The importance of NAD + encourages the design of NadE inhibitors that may be effective against both active and latent tuberculosis. Moreover, the low sequence identity of 23% between Mtb NadE and the human homolog, as well as the presence of NadE-independent NAD + biosynthesis pathways in humans, increases the attraction of NadE as a drug target for Mtb. 7, 13, 17, 18 Despite this promise, few studies explore NadE inhibitors as antitubercular agents. Velu et al. reported a series of tethered dimers as inhibitors of B. subtilis NadE and several Grampositive organisms. 16, 19 One of the most potent B. subtilis NadE inhibitors from this work ( Figure 2A ) yielded an IC 50 (concentration resulting in 50% enzyme inhibition) value of 10 μM against B. subtilis NadE and an MIC (minimum inhibitory concentration) of 1.5 μM against B. subtilis. 16, 19 Boshoff et al. tested several of these tethered dimers against Mtb NadE and Mtb cellular growth. 14 The compounds, however, showed only modest activity. The most potent Mtb NadE inhibitor ( Figure 2B ) gave an IC 50 of 21.8 μM against Mtb NadE and an Mtb MIC of 20 μM. 14 A significant number of compounds as inhibitors of NadE have been synthesized by the Brouillette group. 20, 21 Using a high-throughput assay, they discovered compound 5824, which showed strong inhibition of B. anthracis NadE (IC 50 = 6.4 μM, Figure 2) . 20 According to their modeling results using the B. subtilis homolog, the group predicted that 5824 bound to the NaAD + subsite of NadE. 20 The group next reported a series of the reverse sulfonamide analogs of 5824 that were tested against B. anthracis NadE, B. anthracis NaMNAT, and B. anthracis Sterne. One of their best inhibitors ( Figure 2C ) displayed a B. anthracis NadE IC 50 of 15.3 μM but did not kill B. anthracis cells. 21 In order to evaluate compounds that are active against Bacillus NadE as potential Mtb NadE inhibitors, the similarity between Bacillus and Mtb homologs was explored. Mtb NadE is glutamine dependent and has a glutaminase domain that transports ammonia to the synthetase domain via an ammonia tunnel. 11 Interestingly, NadE from B. subtilis or B. anthracis depends on exogenous ammonia and does not possess a glutaminase domain or an ammonia tunnel. 22, 23 Thus, the amino acid sequences of NadE from B. subtilis, B. anthracis, and only the C-terminal domain of Mtb NadE (i.e., the Mtb NadE synthetase domain that is homologous to the Bacillus NadE enzymes) were aligned. The sequence identity among these enzymes was calculated based on this alignment using MUSCLE 24, 25 ( Table 1) . While the two Bacillus NadEs share 88.6% sequence identity, the Mtb NadE Cterminal domain shares 36.6% sequence identity to the Bacillus subtilis NadE and 34.4% sequence identity to the Bacillus anthracis NadE. We expected high conservation of the active site residues between species, which encourages the design of Mtb NadE inhibitors based on the Bacillus inhibitor structures. Therefore, we chose compound 5824 (3-{4-[(3,4 dichlorophenyl)sulfamoyl]phenyl}-1-(4-nitrophenyl)urea, Figure 2 ) as the parent structure for the current work.
A virtual library of 118 urea-sulfonamide analogs was made. Half of the compounds were sulfonamides, retaining the configuration of parent compound 5824, while half were the 'reversed sulfonamide', corresponding to the opposite configuration. Compounds varied structurally only at ring A, where a variety of substituents were appended. Substituents were selected based on the Topliss approach toward aromatic systems 26 as well as commercially available anilines. Compounds were docked into the crystal structure of Mtb NadE 13 (PDB id: 3DLA) using the Glide tool in Schrodinger, suite 2010 27 . The 100 top-scoring analogs are shown in Table S1 (more negative Glide scores predicting improved binding affinities). Interestingly, the putative binding site of many analogs was predicted to involve the intramolecular ammonia tunnel 11 that transports ammonia from the glutaminase domain to the synthetase domain (Table S2 ). For example, compound 4l (R = 4-H) formed hydrogen bonds with GLY-366 and LEU-399 ( Figure 3A) , and ring A rested in a hydrophobic pocket, the entrance to the tunnel ( Figure 3B ). Based on these modeling results and synthetic feasibility, a series of analogs was selected for synthesis ( Figure 4 ). These compounds could shed light on the influence of ring A structural changes on Mtb NadE inhibition and antibacterial activity.
To prepare the desired compounds, a simple synthetic route was designed (Scheme 1). Substituted anilines 1a-l were combined with 4-acetamidobenzenesulfonyl chloride to obtain compounds 2a-l generally in high yield unless a second recrystallization in ethanol was needed. The deacetylated products (3a-l) were obtained after acid hydrolysis and were purified either by silica column chromatography or recrystallization. The intermediates 3a-l were then combined with 4-nitrophenylisocyanate to yield final compounds 4a-l. Due to production of a sticky side product (likely a urea), purification of some final compounds proved challenging. Such reactions were purified by silica column chromatography and then by recrystallization from acetone to achieve high purity but with substantially reduced yields [28] [29] [30] [31] Compounds were evaluated for inhibition of Mtb NadE measuring their effect on pyrophosphate (PPi) production using the EnzChek Pyrophosphate Assay (ThermoFisher, Waltham, MA). Briefly, PPi formation is coupled to the production of 2-amino-6-mercapto-7-methylpurine at 360 nm. The IC 50 values are shown in Table 2 . The synthesized urea-sulfonamide compounds show a 10-fold range of activity against Mtb NadE. Parent compound 4i (5824) shows poor inhibition of Mtb NadE (IC 50 = 1000 ± 300 μM), contrary to its more potent inhibition of B. anthracis NadE (IC 50 = 6.4 μM). 21 This difference in efficacy is likely due to structural differences between the two homologs (as noted above). Our modeling results show that the binding site of this series of compounds may involve the intramolecular ammonia tunnel of the Mtb NadE. This tunnel is absent in B. subtilis and B. anthracis. Thus, compound 4i likely binds to an alternate site in the Bacillus homologs compared with Mtb NadE.
The new analogs show improved Mtb NadE inhibition relative to the parent compound with most IC 50 values roughly 5-10-fold better than 4i. The most potent Mtb NadE inhibitor of the series is 4f (4-NO 2 ) with an IC 50 value of 90 μM. Comparing unsubstituted analog 41 with other analogs in the series, halogen-substituents are generally not beneficial in terms of Mtb NadE inhibition as compounds 4e, 4j, and 4k were among the least potent of the series. The remaining analogs, 4a-d and 4f-h have similar activities compared to unsubstituted compound 4l and yield a bland structure-activity-relationship profile between these substituents and Mtb NadE inhibition.
To further investigate the binding mechanism of this series of compounds, an ammoniadependent Mtb NadE inhibition assay 12, 32 was performed on the most potent compounds 4d, 4f, 4h and 4l. In this assay, exogenous ammonia is used as the ammonia source for the NadE reaction, as opposed to the ammonia synthesized by the glutaminase domain of the enzyme. As shown in Table 2 , these compounds lose inhibition (IC 50 >200 μM) against Mtb NadE when exogenous ammonia is supplied, and enzymatic activity is restored. This supports our hypothesis that these compounds bind to the intramolecular ammonia tunnel suggested from the modeling study, as well as offering an explanation of the activity difference observed for compound 4i against B. anthracis NadE versus Mtb NadE.
The urea-sulfonamides were also tested for the inhibition of Mtb cellular growth in both rich media (7H9) and minimal media (GAST-Fe). [33] [34] [35] [36] The antitubercular activities of these compounds are shown in Table 2 . All compounds inhibit Mtb growth to a moderate extent with MIC values of 19-100 μg/mL (7H9). The most potent compound is 4e (4-F) with an MIC value of 19 μg/mL (7H9). Again, the structure-activity relationship of the series is flat, indicating this portion of the urea-sulfonamides does not impact antitubercular activities to a great extent.
There remains an urgent need for antitubercular drugs that are highly active and work through new modes of actions. This work builds on the novel design of three-ring ureasulfonamides as NadE inhibitors. The parent compound 4i, shows very different potency against Mtb and B. anthracis NadE homologs, perhaps due to structural differences between the two enzymes. This is supported by our preliminary modeling studies, showing that the binding sites of these compounds may overlap with the ammonia tunnel in Mtb NadE rather than the NaAD + subsite in B. anthracis NadE 20 , as suggested earlier. This hypothesis is reinforced by the loss of activities for the active Mtb NadE inhibitors when treated with exogenous ammonia instead of that from glutamine. This point of difference may be used to design selective inhibitors targeting Mtb NadE over other homologs. While most of the analogs display a 5-10-fold improvement against Mtb NadE over the parent compound, all of the compounds show moderate activity against Mtb whole cell growth. Structural optimization of these compounds is needed, not only to improve activity against both Mtb NadE and Mtb, but also to increase solubility which was noticeably poor in various organic solvents and water. Such compounds would aid in further validating NadE as an effective target for Mtb and other bacterial pathogens.
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Compound 4l (R = 4-H) docked into Mtb NadE (PDB: 3DLA). (A) The green ribbon represents NadE. The ligand and selected protein residues are colored by atom type, and hydrogen bonding is represented by dashed red lines. (B) Using the same NadE orientation, the surface of the enzyme is colored to show the degree of hydrophobicity (darker red indicates more hydrophobic character). Ring A (circled) is shown going into the ammonia tunnel at its entrance. Structure of parent compound 5824 and the analogs prepared in this work.
